-Shares of BriaCell Therapeutics Corp. BCTX, 111.64% more than doubled Wednesday on heavy volume, after the biotechnology company provided upbeat update on its breast cancer treatment.
-The company the average overall survival benefit was 12.0 months, with a top-responder survival of 21.4 months plus 100% resolution of "eye-bulging" tumor, which compares with average 7.2 months to 9.8 months survival in historical comparison treatment trials.
-
-The company the average overall survival benefit was 12.0 months, with a top-responder survival of 21.4 months plus 100% resolution of "eye-bulging" tumor, which compares with average 7.2 months to 9.8 months survival in historical comparison treatment trials.
-
ืืชื ืืืชืืจ
ืืืืืข ืืืคืจืกืืืื ืืื ื ืืืืขืืื ืืืืืช, ืืืื ื ืืืืืื, ืืืขืืฅ ืื ืืืืฆื ืคืื ื ืกืืช, ืืฉืงืขืชืืช, ืืกืืจืืช ืื ืืื ืกืื ืืืจ ืืืกืืคืงืช ืื ืืืืฉืจืช ืขื ืืื TradingView. ืงืจื ืขืื ืึพืชื ืื ืืฉืืืืฉ.
ืืชื ืืืชืืจ
ืืืืืข ืืืคืจืกืืืื ืืื ื ืืืืขืืื ืืืืืช, ืืืื ื ืืืืืื, ืืืขืืฅ ืื ืืืืฆื ืคืื ื ืกืืช, ืืฉืงืขืชืืช, ืืกืืจืืช ืื ืืื ืกืื ืืืจ ืืืกืืคืงืช ืื ืืืืฉืจืช ืขื ืืื TradingView. ืงืจื ืขืื ืึพืชื ืื ืืฉืืืืฉ.